Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Cormedix (NASDAQ:CRMD) but has lowered the price target from $14 to $12.
July 25, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has maintained its Buy rating on Cormedix but has lowered the price target from $14 to $12.
The maintained Buy rating suggests continued confidence in Cormedix's prospects, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100